Literature DB >> 23143147

Resection strategies for neuroendocrine pancreatic neoplasms.

F M Watzka1, C Laumen, C Fottner, M M Weber, A Schad, H Lang, T J Musholt.   

Abstract

INTRODUCTION: Due to their rarity and lack of prospective trials, the optimal treatment of pancreatic neuroendocrine neoplasms (PNENs) is still debated. Recommendations gathered by retrospective analyses of patient data should be based on the new classification of neuroendocrine neoplasms.
METHODS: In a retrospective single-center study (1990 to 2012), 127 patients with PNENs were included. Tumor stage and type of resections were analyzed to evaluate successful treatment strategies.
RESULTS: Seventy-nine patients (62 %) were diagnosed with stage I or II, 48 patients (38 %) with stage III or IV disease; 49.6 % of all PNENs were nonfunctional. Surgical interventions consisted of 50 enucleations, 27 distal resections, and 2 partial duodenopancreatectomies in patients with stage I or II disease. Twenty-eight patients with stage III or IV disease received a distal resection and in 13 patients, a partial duodenopancreatectomy was carried out. Exploration with debulking was performed in seven patients in stages III and IV. Stage-dependent 10-year survival rates were 93.7 (stages I and II, n = 79) and 56.0 % (stages III and IV, n = 48).
CONCLUSIONS: PNENs have a good prognosis if they are well-differentiated and resected completely. Organ-preserving resection does not impair the prognosis in selected cases with stage I or II. In case of hepatic metastasis and advanced tumor stage, surgical reduction can reduce symptoms and improve the survival.

Entities:  

Mesh:

Year:  2012        PMID: 23143147     DOI: 10.1007/s00423-012-1024-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  18 in total

1.  The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.

Authors:  Günter Klöppel; Guido Rindi; Aurel Perren; Paul Komminoth; David S Klimstra
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

2.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.

Authors:  Riccardo Casadei; Claudio Ricci; Daniela Rega; Marielda D'Ambra; Raffaele Pezzilli; Paola Tomassetti; Davide Campana; Francesca Nori; Francesco Minni
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

4.  Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Asima Cheema; Jill Weber; Gang Han; Domenico Coppola; Larry K Kvols
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

5.  Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients.

Authors:  Jan Franko; Wentao Feng; Linwah Yip; Elizabeth Genovese; A James Moser
Journal:  J Gastrointest Surg       Date:  2009-12-09       Impact factor: 3.452

6.  Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.

Authors:  Jonathan R Strosberg; Asima Cheema; Jill M Weber; Masoumeh Ghayouri; Gang Han; Pamela J Hodul; Larry K Kvols
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

7.  TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.

Authors:  G Rindi; M Falconi; C Klersy; L Albarello; L Boninsegna; M W Buchler; C Capella; M Caplin; A Couvelard; C Doglioni; G Delle Fave; L Fischer; G Fusai; W W de Herder; H Jann; P Komminoth; R R de Krijger; S La Rosa; T V Luong; U Pape; A Perren; P Ruszniewski; A Scarpa; A Schmitt; E Solcia; B Wiedenmann
Journal:  J Natl Cancer Inst       Date:  2012-04-23       Impact factor: 13.506

8.  Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.

Authors:  R Bettini; W Mantovani; L Boninsegna; S Crippa; P Capelli; C Bassi; A Scarpa; P Pederzoli; M Falconi
Journal:  Dig Liver Dis       Date:  2008-05-07       Impact factor: 4.088

Review 9.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

10.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.

Authors:  Karl Y Bilimoria; David J Bentrem; Ryan P Merkow; James S Tomlinson; Andrew K Stewart; Clifford Y Ko; Mark S Talamonti
Journal:  J Am Coll Surg       Date:  2007-08-03       Impact factor: 6.113

View more
  9 in total

1.  Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Sanziana Roman; Shelby Reed; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-05-20       Impact factor: 5.344

Review 2.  [Surgical strategies for small sporadic neuroendocrine pancreatic tumors].

Authors:  K Holzer
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

3.  Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms.

Authors:  Toshihiko Masui; Asahi Sato; Kenzo Nakano; Yuichiro Uchida; Akitada Yogo; Takayuki Anazawa; Kazuyuki Nagai; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

4.  PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS.

Authors:  S O Dima; T Dumitrascu; C Pechianu; R T Grigorie; V Brasoveanu; A Sorop; I Lupescu; R Purnichescu-Purtan; A Croitoru; N Bacalbasa; A Tanase; D R Tomescu; V Herlea; I Popescu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

5.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08

Review 6.  Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

Authors:  Anneke P J Jilesen; Casper H J van Eijck; K H in't Hof; S van Dieren; Dirk J Gouma; Els J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

7.  Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Authors:  Young Jin Yoo; Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Hogeun Kim; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

Review 8.  Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation.

Authors:  Ilenia Bartolini; Lapo Bencini; Matteo Risaliti; Maria Novella Ringressi; Luca Moraldi; Antonio Taddei
Journal:  Gastroenterol Res Pract       Date:  2018-07-22       Impact factor: 2.260

9.  Similar Outcomes in Minimally Invasive versus Open Management of Primary Pancreatic Neuroendocrine Tumors: A Regional, Multi-Institutional Collaborative Analysis.

Authors:  Thomas L Sutton; Rodney F Pommier; Skye C Mayo; Erin W Gilbert; Pavlos Papavasiliou; Michele Babicky; Jon Gerry; Brett C Sheppard; Patrick J Worth
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.